Delay in decision on modifying funded access to mifepristone and misoprostol proposal
Source: Pharmac
PHARMAC would like to advise all interested parties that there will be a delay in the decision on a proposal to list mifepristone in...
OIA response: Vinorelbine
Source: Pharmac
31 March 2020
Dear
REQUEST FOR INFORMATION
Thank you for your email of 3 March 2020, requesting information under the Official Information Act 1982 (OIA). ...
March 2020 tender notification
Source: Pharmac
Alfacalcidol
Cap 0.25 mcg
Alfacalcidol
Cap 1 mcg
Alfacalcidol
Oral drops 2 mcg per ml
Alprostadil
Inj 10 mcg
Alprostadil
Inj 20 mcg
Betamethasone Dipropionate
Crm 0.05% in propylene glycol base
Betamethasone Dipropionate
Oint 0.05% in...
Decision to fund ivacaftor (Kalydeco) for people with cystic fibrosis with the G551D mutation
Source: Pharmac
What we’re doing
We are pleased to announce a decision to fund ivacaftor (Kalydeco) for the treatment of people with cystic fibrosis with the...
Decision to change the funded brand of labetalol tablets
Source: Pharmac
What we’re doing
PHARMAC has made a decision to make changes to the funded brand of labetalol tablets, which may be used in the...
RFP – supply of diabetes agents: SGLT-2 inhibitors, GLP-1 agonists and DPP-4 inhibitors –...
Source: Pharmac
If you wish to submit a proposal, you must submit it to PHARMAC via the Government Electronic Tenders Service (GETS) (www.gets.govt.nz(external link)) no...
Decision to list medical devices supplied by Hologic (Australia & New Zealand) Pty Limited
Source: Pharmac
Our response to what you told us
We appreciate the time people took to respond to this consultation.
A summary of the main themes raised...
